Both companies heavily leverage AI to accelerate research and development. New Limit's models explain 50% of experimental variation and have doubled the speed of discovering effective transcription factor sets, while Until reports at least a 2x speed improvement in R&D iteration cycles.
The conversation contrasts two ambitious strategies for extending human healthspan. New Limit focuses on "resetting" the biological clock through epigenetic reprogramming to restore youthful cell function, while Until aims to "pause" time via cryopreservation, allowing patients to await future cures.
The founders discuss the challenge of resource allocation in deep tech. New Limit employs a 70/30 budget split between near-term and high-risk projects, exemplified by a successful bet on a multiplexed approach that yielded a 5x efficiency gain in molecular construction.
The speakers frame AI as the second major revolution in therapeutic development after recombinant DNA. They believe these new computational tools will enable the creation of entirely new classes of medicine that move beyond the single-gene, single-target paradigm that dominates the pharmaceutical industry today.
Keep pulling the thread on Laura Deming and Jacob Kimmel.